Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: SONATA
Published 2025-12-21 · Last reviewed 2025-12-28 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Zaleplon is a short-acting non-benzodiazepine hypnotic (“Z-drug”) approved for insomnia, primarily targeting sleep onset.
Because duration is short, zaleplon is generally a better fit for difficulty falling asleep than for frequent nighttime awakenings; if sleep maintenance is the primary problem, consider other options rather than increasing hypnotic burden.
Key safety issues are complex sleep behaviors (boxed warning), next-day impairment (especially if taken with less than a full night of sleep remaining), and additive sedation with alcohol or other CNS depressants —risks that are amplified in older adults and in serious mental illness with polypharmacy.
The zaleplon compare view, zaleplon evidence feed, and zaleplon print page can support aligning sleep goals with safety planning.
Treat zaleplon as a time-limited adjunct alongside CBT-I and sleep hygiene; avoid chronic, open-ended refills. Use short prescriptions, define a stop plan, and discontinue if complex sleep behaviors or unsafe next-day impairment emerge.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Positive allosteric modulator of GABA-A receptors producing hypnotic effects.
Classified as a “Z-drug”; hypnotic/sedative effects are dose dependent and interact strongly with other CNS depressants.
Like other hypnotics, zaleplon can reduce symptoms but does not treat the underlying cause of insomnia; pair medication use with behavioral sleep strategies and treatment of comorbid psychiatric conditions.
Sources: FDA/DailyMed label; AASM insomnia guideline; evidence reviews.